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Abstract
Many commonly used non-steroidal anti-inflammatory drugs (NSAIDs) also cause gastrointestinal toxicity, including the
development of life-threatening peptic ulcers. We report that mast cell-deficient mice have an extremely high incidence of
severe peptic ulceration when exposed to the NSAID piroxicam. This enhanced ulcer susceptibility can be reversed by
reconstitution with mast cells. Furthermore, wild type mice treated with diphenhydramine hydrochloride, a commonly used
antihistamine that blocks histamine H1 receptors, develop a similarly high incidence of peptic ulcers following piroxicam
exposure. The protective effect of mast cells is independent of TNF, blockade of H2 receptors, or acid secretion. These data
indicate a critical role for mast cells and the histamine that they produce in prevention and/or repair of piroxicam-induced
gastric mucosal injury. Additional studies will be required to determine whether this represents a NSAID class effect that can
be exploited to develop novel therapeutic strategies to limit the incidence of NSAID-induced side effects in humans.
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Introduction
Peptic ulcers result from an imbalance between factors that
damage the mucosa and the normal mucosal defense and repair
mechanisms. Examples of factors that predispose to ulceration
include Helicobacter pylori infection, stomach acid, stress, alcohol,
tobacco, and non-steroidal anti-inflammatory drugs (NSAIDs)
[1,2]. Thirty million people use NSAIDs daily, with frequent use
reported by up to 70% of some populations [3–6]. This
widespread use makes NSAID-associated peptic ulcer disease
(PUD) a significant public health concern which is associated with
high annual treatment costs [7,8].
Inhibition of cyclooxygenases (COX) that produce prostaglan-
dins (PGs) is thought to account for both the anti-inflammatory
effects and the gastrointestinal (GI) toxicities of NSAIDs. PGs
coordinate secretion of protective mucus, surfactant, and bicar-
bonate, reduce acid secretion, decrease epithelial permeability,
increase mucosal blood flow, and enhance inflammation [9,10].
Although it was hypothesized that selective inhibition of COX-2
could control pain while preventing adverse effects, COX-2-
specific NSAIDs still have GI toxicity [11,12] and they also
increase risk of cardiovascular events [13–15]. Studies in COX-1
knockout mice suggest that NSAID-induced damage can be
unrelated to COX-1 inhibition and PGE2 levels [16,17]. Possible
mechanisms include bile reflux, since gastric ulcers related to
systemic NSAID administration can be reduced or eliminated by
blocking or diverting bile flow [18,19]. NSAIDs may also
compromise mucosa through their inherent acidic properties or
through effects on epithelial cell proliferation and apoptosis,
mucosal blood flow, or production of growth factors or
antioxidants.
Ulcer healing requires formation of granulation tissue, angio-
genesis, re-epithelialization, proliferation, and tissue remodeling.
Mast cells have been shown to contribute to wound healing in the
skin by modifying neutrophil trafficking, angiogenesis, and
remodeling of the extracellular matrix. In this study, wild type
(WT) and mast cell-deficient mice were used to investigate the role
of mast cells in NSAID-induced gastrointestinal injury and
healing. Results showed that mast cell-deficient mice were
exquisitely sensitive to peptic ulceration induced by the NSAID
piroxicam. This sensitivity could be reversed by mast cell
reconstitution or by administration of antihistamines to WT mice.
Taken together, the data suggest a critical role for mast cells and
the histamine they produce in repair of piroxicam-induced gastric
mucosal injury.
Results
Mast cell-deficient Sash mice are highly susceptible to
piroxicam-induced peptic ulceration
Mast cell-deficient Sash mice were noted to lose weight very
rapidly when fed powdered chow containing 200 ppm piroxicam
(Figure 1A). Necropsy showed marked gastric distension, with
stomachs increased to $46 normal size in 17 of 24 (71%) of
exposed mice (Figure 1B, C; Figure 2A). Retained food, fluid, and
air suggested gastric outlet obstruction. Ulcers were present at the
gastro-duodenal junction in 15 of 18 Sash mice examined
histologically (Figure 1D; Figure 2B), with marked inflammatory
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Ulceration was much less common in piroxicam-exposed WT
mice (4 of 13 mice, 31%; Figure 2B; p,0.01 vs. Sash mice) and,
when ulcers were present, they were smaller and did not result in
gastric outlet obstruction (Figure 1E; Figure 2A).
Susceptibility to severe ulceration and gastric outlet
obstruction following piroxicam-exposure is mast cell-
dependent
To determine the role of mast cells in susceptibility to
piroxicam-induced peptic ulceration, mast cell-deficient Sash mice
[20,21] were reconstituted with bone marrow-derived mast cells
(BMMC) prior to piroxicam exposure. Reconstitution with
BMMC eliminated the susceptibility of Sash mice to gastric outlet
obstruction (Figure 2A) and restored the frequency of gastric
ulceration in response to piroxicam to a level statistically similar to
what is observed in WT mice (Figure 2B). Mast cells in various
stages of degranulation could be observed adjacent to areas of
ulceration at the gastrointestinal junction of both wild type and
mast cell-reconstituted Sash mice (Figure 3).
The protective effect of mast cells is not due to TNF
production
Activated mast cells release granules containing histamine,
heparin, basic proteinases (e.g. tryptase), and chemokines, as well
as the pro-inflammatory cytokine TNF. Mast cell-derived TNF
was previously shown to be critical for protection against infections
and for development of adaptive immune responses against
pathogens [22–24]. To test the role of TNF in NSAID-induced
ulceration, mice globally deficient in TNF were exposed to
200 ppm piroxicam. Peptic ulcers occurred in 4 of 11 Tnf
2/2 mice
and gastric outlet obstruction was observed in 1 of 11 mice. These
incidence rates are statistically similar to what was observed in WT
mice (Figure 2). Thus, TNF is not required for protection against
peptic ulceration induced by piroxicam.
Mast cell-derived histamine protects against piroxicam-
induced peptic ulceration
To test the importance of histamine in piroxicam-induced
peptic ulceration, WT and Sash mice were pre-treated with
antihistamines provided in drinking water for 2 days prior to and
during a 5 day exposure to piroxicam. Treatment with the
histamine H1-receptor antagonist diphenhydramine hydrochlo-
ride did not affect the incidence or severity of peptic ulcers in
piroxicam-exposed Sash mice (Figure 4), consistent with their lack
of mast cell sources of histamine. However, similar treatment of
piroxicam-exposed WT mice gave a dose-dependent increase in
ulcers, with ulcer incidence at 40 mg/ml diphenhydramine
equivalent to that seen in Sash mice (Figure 4A). In a separate
study, treatment of WT mice with the histamine H1-receptor
antagonist hydroxyzine hydrochloride at 40 mg/ml in drinking
water prior to and during piroxicam exposure also showed a trend
toward increased ulcer incidence (60%; n=10). These data
strongly implicate mast cell-derived histamine acting through H1
receptors as a mechanism that protects against NSAID-induced
peptic ulceration. However, ulcers in antihistamine-treated WT
Figure 1. Mast cell-deficient Sash mice are highly susceptible to NSAID-induced peptic ulcers. A. Mean weight data is shown for 13 Sash
and 10 wild type (WT) mice exposed to 200 ppm piroxicam in their diet. SEMs ranged from 0.4–1.6% of pre-treatment weight; error bars were
omitted for clarity. The rapid weight loss correlates with decreased intake of food and water. Euthanasia for humane reasons was typically required
on days 4–6. * indicates p#0.05 relative to WT mice. Piroxicam-exposed Sash mice demonstrated marked gastric distension by gas and fluid (B,
bottom half of panel C) compared with Sash mice not exposed to piroxicam (labeled ‘‘control’’ in panel C). Histologic examination showed ulceration
at the gastroduodenal junction (E) of Sash mice, with marked inflammatory cell infiltration and edema that led to gastric outlet obstruction. WT mice
(D) do not typically develop ulcers or changes in stomach size with piroxicam exposure.
doi:10.1371/journal.pone.0023669.g001
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both histologically and based on the lack of gastric outlet
obstruction in diphenhydramine-treated WT mice. Treatment
with the histamine H2-receptor antagonist ranitidine had no effect
on the incidence of peptic ulcers in piroxicam-treated WT or Sash
mice (Figure 4B).
Inhibition of acid secretion does not protect against
piroxicam-induced peptic ulcers
Blocking secretion of mucosa-damaging acid has been recom-
mended to decrease the chance of NSAID-induced GI toxicity
[25]. To test this, Sash and WT mice were treated with the proton
pump inhibitor (PPI) omeprazole for 7 days prior to and
continuing during the 5 days of piroxicam exposure. The pH of
gastric lavage fluid in a separate cohort of mice analyzed after 7
days of PPI treatment increased from 2.960.3 (mean 6 SEM;
n=8) in control mice to 4.460.3 (n=3) in PPI-treated mice
(p=0.01). This corresponds to a decrease in acid secretion of 97%.
However, despite this efficacy in acid reduction, omeprazole
treatment did not decrease the incidence of piroxicam-induced
peptic ulcers in Sash mice and most of these mice still developed
marked gastric enlargement or gastric outlet obstruction (Figure 5).
All mice with stomach enlargement .46normal had ulcers at the
gastro-duodenal junction. However, gastric enlargement 2–46
normal was seen in 2 Sash mice that had acute gastritis and edema
of the stomach wall without frank ulceration. PPI treatment also
did not affect incidence of piroxicam-induced ulcer in WT mice (1
of 5 mice=20%; compare to Figures 1, 2).
COX inhibition alone is insufficient to explain ulcer
susceptibility in Sash mice
Piroxicam has significant activity against both COX-1 and
COX-2 enzymes. To test the role of COX inhibition in ulcer
susceptibility, Sash and WT mice were exposed to either the COX-
1 inhibitor ketorolac, the COX-2 inhibitor etodolac, or both,
formulated at 20 mg/kg powdered rodent chow for 7 days. None
of these mice experienced significant weight loss or gastric
enlargement suggestive of gastric outlet obstruction. Ulcers were
seen histologically on day 7 in 1 of 5 Sash mice exposed to
ketorolac, 0 of 5 mice given etodolac, and 0 of 5 mice given both
drugs. Thus inhibition of COX-1, COX-2, or both enzymes alone
seems inadequate to explain the gastric toxicity of piroxicam in
Sash mice.
Piroxicam impairs survival and proliferation of gastric
epithelial cells
The AGS gastric epithelial cell line was used to further
investigate the toxicity of NSAIDs on gastric epithelial cells in
vitro. Ketorolac, etodolac, and piroxicam all reduced cell
proliferation, but the magnitude of effect was greatest for
piroxicam (Figure 6A). Piroxicam also reduced cell survival
relative to control and to ketorolac or etodolac (Figure 6B). We
previously showed that piroxicam induced apoptosis in colonic
epithelial cells in vivo (40), however the decreased survival of
piroxicam-exposed AGS gastric cells was not due to increased
apoptosis (Figure 6C). Taken together, the data suggest that
piroxicam has a direct toxic effect on gastric epithelial cells that
both decreases their proliferation and decreases their survival via
non-apoptotic mechanisms.
Discussion
The data show that mast cell-deficient Sash mice develop peptic
ulcers in response to oral exposure to piroxicam. These ulcers are
severe, leading to occlusion of the gastric outlet by inflammation.
Ulceration and gastric outlet obstruction in these mast cell-
deficient mice are both prevented by restoring mast cells. This
susceptibility to ulceration can be recapitulated by treating WT
mice with diphenhydramine, an antihistamine that blocks the
histamine H1 receptor. Taken together, these data indicate that
mast cell-derived products, including histamine acting through H1
receptors, are vital for prevention and/or repair of NSAID-
induced gastric epithelial injury.
The first line of gastric mucosal defense consists of luminal
factors such as mucus, bicarbonate, and surfactants. Epithelial
factors that provide further protection include tight adherence of
cells, high resistance of apical membranes to acid, rapid extrusion
of apoptotic cells, and rapid restitution following epithelial damage
(e.g. a denuded rat stomach can cover 95% of its area with
epithelial-appearing cells in 1 hour [26]). Extruded plasma can
mix with mucus released by damaged epithelial cells to form a
protective mucoid cap [27]. If these protective measures fail,
inflammatory responses and ulcer healing are invoked [28].
Granulation tissue consisting of fibroblasts, macrophages, and
angiogenic endothelial cells forms at the ulcer base within 48–
72 hours. Viable epithelial cells at the ulcer margin de-differen-
tiate, proliferate, and migrate onto the granulation tissue to cover
Figure 2. Mast cell-deficient mice are more susceptible to
peptic ulceration when exposed to piroxicam. Significantly more
Sash mice developed grossly evident gastric outlet obstruction defined
as gastric enlargement .46 normal (A) and histologically detected
peptic ulcers (B) when exposed to piroxicam, compared with WT or
Tnf
2/2 mice. Both the increased sensitivity to peptic ulcers and gastric
outlet obstruction appeared to be mast cell-dependent, since they
reversed when Sash mice were reconstituted with mast cells (Sash+GFP-
MC), but were not TNF-dependent since Tnf
2/2 mice had a similar
incidence of gastric ulceration and gastric outlet obstruction as WT
mice. * indicates p#0.05 relative to WT.
doi:10.1371/journal.pone.0023669.g002
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leaving an underlying scar [29].
Involvement of mast cells in gastric ulceration and healing has
been suggested previously [28,30–34], but conclusive proof was
not obtained for either effect or mechanism. In skin, mast cells
primarily appear to be involved in the initial response to epithelial
injury [reviewed in 35]. Mast cell degranulation occurs quickly in
proximity to a wound [36]. Dermal wound healing is impaired in
mast cell-deficient Kit
W/Kit
W-v mice, with decreased immediate
increase in vascular permeability and delayed wound closure
[35,37]. These findings could be reproduced by treating WT mice
with a histamine H1-receptor antagonist, but not with H2-
receptor or TNF antagonists. Scald wounds also showed delayed
healing in mast cell-deficient mice [38].
We found a similar striking impairment of NSAID-induced
gastric wound healing in mast cell-deficient Sash mice. Unlike the
mast cell-deficient Kit
W/Kit
W-v mice used in previous studies
[31,39], Sash mice do not lack TCRcd T cells and do not develop
spontaneous gastric ulcers. However, they do appear to lack
interstitial cells of Cajal, which may predispose them to bile reflux
that can also be ulcerogenic [40]. The gastric outlet obstruction
seen in NSAID-exposed Sash mice would completely eliminate any
potential reflux of bile, although this does not rule out bile acid
gastric toxicity as a component of the initial insult. It is also
possible that the role of mast cells in reducing NSAID-induced
injury may be different in WT vs. Sash mice. However, taken
together, the observations that reconstitution of Sash mice with
mast cells eliminated susceptibility to ulcers and that ulcer
susceptibility could be reproduced in WT mice by blockade of
histamine H1-receptors provides definitive evidence that mast cells
are the primary factor in the observed phenotype, rather than
epithelial abnormalities induced from bile reflux from the Kit
W-sh
genotype. Mast cell TNF production can also be eliminated as a
mechanism for protection from gastric ulcers since TNF-deficient
mice did not show increased ulcer susceptibility. Histamine can
also be produced by platelets, but the similarity in phenotype
between the Sash mice and wild-type mice treated with
antihistamines suggests mast cell-derived histamine as the primary
contributor.
Other mast cell-produced factors may also play a role in
protection against NSAID-induced injury and/or facilitation of
mucosal repair. FGF2 is produced by mast cells and can help
prevent and heal NSAID-related ulcers [41,42]. Higher mucosal
tryptase levels were seen in humans infected with H. pylori strains
that were less likely to cause ulcers, suggesting that mast cell-
derived tryptase may promote mucosal turnover and healing [43].
Figure 3. Mast cells in various stages of degranulation are present at the site of peptic ulceration. Hematoxylin and eosin- (panel A) and
toluidine blue-stained sections (panels B–F) show a peptic ulcer located at the junction between the stomach (s) and duodenum (d). Arrowheads
denote the extent of the ulcerated region. The intense purple staining adjacent to the arrowheads in panel B is derived from necrotic debris,
inflammatory cells, and large numbers of metachromatic granules. Panel C shows the boxed region from panel B at higher magnification. Arrows
point out mast cells in various stages of degranulation, as shown in panels D, E, F. Bar represents 200 mm in panels A and B and 100 mm in panel C.
doi:10.1371/journal.pone.0023669.g003
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mitogen following wounding [44].
It is important to note that these studies only used the NSAID
piroxicam as an ulcerogenic stimulus. Thus additional studies will
need to be performed to determine whether these results represent
a NSAID class effect that can be exploited to limit the incidence of
NSAID-induced side effects in humans. Despite considerable
study, the physical and biochemical properties necessary for an
NSAID to exhibit gastric toxicity remain poorly understood. The
piroxicam concentration required to effectively inhibit COX
enzymes in vitro is 1–5 mM [45]. Incubation with piroxicam
concentrations ranging up to 100 mM inhibited release of
histamine from rat peritoneal mast cells by a maximum of 25–
34% [45,46]. However, piroxicam at concentrations ranging from
0.001–100 mM did not affect IgE-induced histamine release from
human synovial mast cells [47]. Since decreased histamine activity
induced by administration of antihistamines that block H1
receptors makes wild type mice more susceptible to piroxicam-
induced peptic ulceration, it is possible that decreased histamine
release by mast cells in the presence of piroxicam may contribute
to the ulcerogenic properties of this NSAID. However, inhibition
of mast cell histamine release cannot account for the increased
ulcer susceptibility observed in Sash mice, which lack mast cells.
Although the observations reported here were made in
genetically-modified mice that lack mast cells, they have
considerable relevance to human health. The recognition that
mast cells and the histamine that they produce is important to
mucosa during NSAID administration provides mechanisms that
may be targetable to prevent NSAID-related gastric toxicity.
Furthermore, although no mast cell-deficient humans have yet
been reported, self-treatment with antihistamines at doses
sufficient to impair mast cell function is common in atopic
individuals. Concomitant NSAID and antihistamine use (e.g. in
over-the-counter cold medications) also commonly occurs in the
setting of common viral or bacterial respiratory infections.
The concept that histamine acting via histamine H-1 receptors
may be necessary for appropriate ulcer healing may sound
counter-intuitive, given that histamine H-2-receptor antagonists
(H2RAs) are prescribed for acid reduction that is widely
recognized to facilitate healing of peptic ulcers. Note that the
H2RA ranitidine had no effect on ulcer incidence in our studies. A
Figure 4. Effect of antihistamines on piroxicam-induced peptic
ulceration. A. Treatment with the H1 receptor antagonist diphenhy-
dramine increased histologically detected peptic ulcers in WT mice
exposed to piroxicam (black bars; n=7–9 per group), to a level
comparable in mast cell-deficient Sash mice treated with piroxicam
alone (gray bar; n=18). Diphenhydramine did not affect ulcer incidence
in Sash mice exposed to piroxicam (nor shown; n=6; p,0.50). B.
Treatment with the H2 receptor antagonist ranitidine (R; dose=1.8 mg/
ml in drinking water) did not affect the incidence of piroxicam-induced
peptic ulcer in either WT (black bars) or Sash mice (gray bars). The
numbers of mice studied were: WT (n=13); WT+R (n=9); Sash (n=18);
Sash+R (n=7). For both panels, * indicates p,0.05 compared to WT
mice treated with piroxicam alone.
doi:10.1371/journal.pone.0023669.g004
Figure 5. Acid inhibition with the proton pump inhibitor omeprazole does not protect mast cell-deficient mice from development
of NSAID-induced peptic ulceration or gastric outlet obstruction. * indicates p,0.05 compared with WT mice treated with piroxicam alone.
Gastric distension by large amounts of gas is readily apparent (arrowhead) in this gross photograph of an omeprazole-reated Sash mouse on day 5 of
piroxicam treatment.
doi:10.1371/journal.pone.0023669.g005
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prevent NSAID-induced ulcers in the duodenum of humans, but
not the stomach [48]. Individual trials have reached similar
conclusions with H2RAs either being ineffective or less effective at
preventing gastric ulcers associated with aspirin or NSAIDs, either
alone or in comparison to duodenal ulcers [49–53]. In any case,
our studies clearly show that acid reduction cannot compensate for
the lack of mast cells in protection against NSAID-induced gastric
ulceration.
Taken together, our studies show that mast cells and histamine
acting via H1 receptors play a heretofore unrecognized role in
protection against and/or repair of ulceration induced by the
NSAID-piroxicam. These findings corroborate known clinical
information regarding diminished efficacy of H2RA in the
prevention of NSAID-induced gastric ulcers and call for further
investigation into the roles of mast cell-produced factors in the
pathogenesis and repair of peptic ulcers induced by piroxicam or
other NSAIDs.
Materials and Methods
Animal studies
Wild type C57BL/6 mice, mast cell-deficient Kit
W-sh/Kit
W-sh
(Sash) mice (strain name=B6.Cg-Kit
W-sh/HNihrJaeBsmJ; stock
#005051), mice transgenic for global expression of green
fluorescent protein (GFP) (strain name=C57BL/6-Tg(UBC-
GFP)30Scha/J; stock # 004353), and mice deficient in TNF
(strain name=B6.129S6-Tnf
tm1Gkl/J; stock # 005540) were
obtained from Jackson Laboratories (Bar Harbor, ME). Where
indicated, Sash mice were reconstituted by intraperitoneal injection
of 10
7 bone marrow-derived mast cells (BMMC) in 100 ml PBS.
BMMC were derived in vitro as described previously [54] using
bone marrow from GFP mice to facilitate documentation of
reconstitution. Mast cell-reconstituted Sash mice were used 12–16
weeks post-reconstitution and compared with age-matched
controls.
All animal studies were approved by the Institutional Animal
Care and Use Committee of Duke University (protocol numbers
A151-09-05 and A225-06-07). Sentinel mice exposed repetitively
to dirty bedding from the mice used in this study were negative for
parasites by microscopic exam, negative for Citrobacter rodentium by
fecal culture, negative by serology for a panel of 22 murine
protozoal, bacterial, and viral pathogens, including murine
parvovirus, murine hepatitis virus, and murine norovirus, and
negative for helicobacter species by fecal PCR.
Model of NSAID-Induced Peptic Ulcers
NSAID was given in powdered rodent chow (LabDiet 5001,
Purina, Framingham, MA) at 200 mg/kg diet for piroxicam and
20 mg/kg diet for ketorolac and etodolac. This dose of piroxicam
was chosen since it has been commonly used in mice, particularly to
trigger the development of chronic colitis in mouse strains that
are genetically susceptible to developing inflammatory bowel
disease (IBD), but does not cause colitis in WT or Sash mice
[54–56]. Mice were monitored daily for weight loss and for food
consumption on a per cage basis. Where indicated, omeprazole was
added to powdered diet at 400 mg/kg diet, a dose previously
documented to decrease acid secretion in mice [57]. The effect of
omeprazole on gastric pH was confirmed following euthanasia by
lavage of stomach for 1 min with 0.5 ml of purified water (pH 5.0).
Collected lavage fluid was centrifuged for 5 min (14,000 rpm in a
microfuge) prior to pH determination. Histamine antagonists were
supplied in drinking water at 0.008 or 0.040 mg/ml for diphenhy-
dramine or hydroxyzine hydrochloride and 1.8 mg/ml for
ranitidine. Food and water consumption were measured to ensure
comparable drug doses between groups.
Euthanasia was performed when mice lost .15% of body
weight, became moribund, or had completed 5–7 days of NSAID
Figure 6. NSAIDs differentially affect apoptosis and prolifera-
tion of gastric epithelial cells in vitro. A. All three NSAIDs tested
decreased proliferation of AGS cells compared with vehicle (DMSO)
alone, as measured by changes in CFSE incorporation over 3 days of
culture, with the largest decrease seen in piroxicam-treated cells (*
indicates p,0.05 vs. vehicle; ** p#0.04 vs. vehicle, ketorolac, or
etodolac). B. Survival of AGS cells measured by a tetrazolium dye-based
assay is significantly decreased by exposure to piroxicam, but not to
keterolac or etodolac. Data shown (mean 6 SD; n=12) was obtained
after 4 hrs of treatment. * indicates p,0.05 compared with DMSO
control. C. Treatment with the NSAIDs ketorolac or etodolac, but not
piroxicam, significantly increased apoptosis as indicated by increased
caspase 3 and 7 activity, shown here at 24 hrs (mean 6 SD; n=3).
doi:10.1371/journal.pone.0023669.g006
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excised en bloc for examination using hematoxylin and eosin-
stained paraffin sections. The primary outcome measure was the
presence of ulcer in the stomach or duodenum. Granulation tissue
in the stomach or duodenal wall was required for the diagnosis of
ulcer. Lesser degrees of damage were classified as gastritis/enteritis
(presence of neutrophils) or erosions (loss of epithelium). Gastric
enlargement due to outlet obstruction was used as an indicator of
ulcer severity and was classified grossly into categories of not
enlarged, enlarged 2–46normal, and enlarged .46normal.
In Vitro Studies
AGS gastric epithelial cells were obtained from the American
Type Culture Collection (Manassas, VA) and cultured in F-12
Kaighn’s nutrient mixture (Invitrogen Gibco 21127) +10%
FBS+pen/strep with and without 1 mM piroxicam, etodolac, or
ketorolac. Cell survival was assessed using a tetrazolium dye-based
assay (CellTiter96 AQ, Promega). Relative amounts of apoptosis
were determined by measuring activation of caspase-3/7 using a
fluorescent substrate assay (Apo-ONE, Promega). Cellular prolif-
eration was measured by flow cytometric quantitation of changes
in content of carboxyfluorescein succinimidyl ester (Guava Cell-
Growth Kit, Guava Technologies).
Data Analysis
The incidence of ulceration or gastric outlet obstruction
between groups was compared using Fisher’s exact (chi squared)
test. Weight loss, gastric pH, and results from in vitro studies were
compared using Student’s t-test. A value of p#0.05 was considered
to be significant.
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